PanTher Presents Phase 1 Trial-In-Progress Poster for Pancreatic Cancer Study at American Society of Clinical Oncology Gastrointestinal Cancers Symposium
PanTher Therapeutics presents “Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma – A Trial in Progress” poster at the American Society for Clinical Oncology 2023 Gastrointestinal Cancers Symposium (ASCO-GI), taking place in San Francisco, Calif., The poster highlights the trial-in-progress for the treatment of borderline resectable or locally advanced pancreatic ductal adenocarcinoma ongoing in Australia. PanTher Therapeutics’ CEO Laura Indolfi and study Principal Investigator John Zalcberg are present to answer any questions.
PanTher Therapeutics Billboard is Live in Times Square, New York, NY
PanTher Therapeutics’ mission of Attacking Cancer at the Source™ is shared from the famous Times Square billboards in New York City November 7-13, 2022. As part of a sponsored campaign with Brex, PanTher displays their mission to the mass of people visiting the major commercial intersection, tourist destination, and entertainment hub that is Times Square.
Read More about PanTher Therapeutics Billboard is Live in Times Square, New York, NY
PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment
PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, received a $14.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will be used to expand clinical development through Phase 2 of PanTher’s lead investigational therapy, PTM-101, a minimally invasive, implantable treatment for non-metastatic pancreatic cancer that provides direct, sustained release of a known therapeutic agent at the tumor site.
PanTher Reimagines Cardiology Interventions As Precision Oncology Platform (Requires login)
Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors. PanTher Therapeutics’ Sagitarri™ platform brings a novel spin to traditional oncology drugs, helping deliver active ingredients to the tumor without affecting the bloodstream leveraging interventional oncology procedures.
PanTher Therapeutics Secures Patent for Anticancer Drug-Eluting Stent
PanTher announced that a methods-of-use patent for a deployable anticancer drug-eluting stent, exclusively licensed to PanTher, has been issued by the USPTO. The patent increases the potential applicability of PanTher’s proprietary Sagittari™ treatment platform, which focuses on direct, localized, and sustained delivery of proven and novel therapeutic agents to attack cancer at the source. PanTher also announced Dan Wildman as a strategic advisor. A seasoned executive with more than 35 years of experience in the MedTech industry, Mr. Wildman previously led the Digital Surgery Strategy initiative at Johnson & Johnson and served as worldwide president of DePuy Synthes Spine and Ethicon Biosurgery.
Read More about PanTher Therapeutics Secures Patent for Anticancer Drug-Eluting Stent
PanTher’s approach of “Attacking Cancer the Source” featured in the Nature Biopharma Dealmakers publication focused on the oncology landscape
PanTher Therapeutics is targeting solid tumors through direct, localized, and sustained delivery of therapeutic agents. The company’s lead program is in a phase 1 trial, and the company is seeking partners to further develop its platform. Leveraging decades of material science, pharmacology, and cancer biology, PanTher’s innovative approach is truly differentiated from current technologies. In a highly competitive innovative drug discovery market, PanTher’s technology focuses on optimizing the route of administration to unlock a drug’s full potential.
